An open-label, multicenter, phase I, dose escalation study with phase II expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma Journal Article
| Authors: | El Dika, I.; Lim, H. Y.; Yong, W. P.; Lin, C. C.; Yoon, J. H.; Modiano, M.; Freilich, B.; Choi, H. J.; Chao, T. Y.; Kelley, R. K.; Brown, J.; Knox, J.; Ryoo, B. Y.; Yau, T.; Abou-Alfa, G. K. |
| Article Title: | An open-label, multicenter, phase I, dose escalation study with phase II expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma |
| Abstract: | Lessons Learned: TKM-080301 showed a favorable toxicity profile at the studied dose. TKM-080301 targeting PLK1 through small interfering RNA mechanism did not demonstrate improved overall survival in patients with advanced hepatocellular carcinoma compared with historical control. Preliminary antitumor activity as shown in this early-phase study does not support further evaluation as a single agent. Background: Polo-like kinase 1 (PLK1) is overexpressed in hepatocellular carcinoma (HCC). Knockdown of PLK1 expression by PLK1 small interfering RNA (siRNA) in an HCC cell line showed reduced expression in RNA-induced silencing complex and a reduction in cell proliferation. Methods: A 3 + 3 dose escalation plus expansion cohort at the maximum tolerated dose (MTD) was implemented. Patients with HCC, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, and Child-Pugh score A received TKM-080301 as an intravenous infusion once every week for 3 consecutive weeks, repeated every 28 days. Results: The study enrolled 43 patients. The starting dose of TKM-080301 was 0.3 mg/kg, and MTD was declared at 0.75 mg/kg. Following the development of grade 4 thrombocytopenia in two subjects on the expansion cohort, the MTD was redefined at 0.6 mg/kg. Four patients did not have any evaluable postbaseline scan. Of the other 39 subjects who had received at least 0.3 mg/kg, 18 subjects (46.2%) had stable disease (SD) by independent RECIST 1.1 criteria. By Choi criteria, eight subjects (23.1%) had a partial response (PR). For 37 assessable subjects, with 2 subjects censored, median progression-free survival (PFS) was 2.04 months. Median survival for the whole study population was 7.5 months. Conclusion: TKM-080301 was generally well tolerated. In this early-phase study, antitumor effect for TKM 080301 was limited. Further evaluation as a single agent in large randomized trials is not warranted. © AlphaMed Press; the data published online to support this summary are the property of the authors |
| Journal Title: | The Oncologist |
| Volume: | 24 |
| Issue: | 6 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-06-01 |
| Start Page: | 747 |
| End Page: | 748, e214-e218 |
| Language: | English |
| DOI: | 10.1634/theoncologist.2018-0838 |
| PROVIDER: | scopus |
| PUBMED: | 30598500 |
| PMCID: | PMC6656521 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work